Matches in Wikidata for { <http://www.wikidata.org/entity/Q63334832> ?p ?o ?g. }
Showing items 1 to 50 of
50
with 100 items per page.
- Q63334832 description "clinical trial" @default.
- Q63334832 description "ensayu clínicu" @default.
- Q63334832 description "klinisch onderzoek" @default.
- Q63334832 description "клінічне випробування" @default.
- Q63334832 name "Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors" @default.
- Q63334832 type Item @default.
- Q63334832 label "Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors" @default.
- Q63334832 prefLabel "Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors" @default.
- Q63334832 P1132 Q63334832-6997166A-A66B-430D-9C32-ACA094128B73 @default.
- Q63334832 P1476 Q63334832-3E5BEF6C-EEFC-4E4A-AA89-429B01E493A2 @default.
- Q63334832 P17 Q63334832-20E0EB59-7B52-4A4A-8AC1-962747EACC00 @default.
- Q63334832 P17 Q63334832-838CF398-EB42-4568-9341-FDF69BFEFB62 @default.
- Q63334832 P17 Q63334832-A75CDBC6-DB75-46E2-8DEE-71BF03A1DF29 @default.
- Q63334832 P17 Q63334832-C837C646-3AE6-4684-BD01-DA54606FED06 @default.
- Q63334832 P2899 Q63334832-0FFF1F6D-9C48-47AB-98AD-FD5FDD61E0AC @default.
- Q63334832 P3098 Q63334832-A1B85571-7A82-448B-AC32-1B107B839A44 @default.
- Q63334832 P31 Q63334832-FF8955EF-A6A0-46A0-872A-B737EF90632A @default.
- Q63334832 P4844 Q63334832-317F4BF2-5E14-4E09-AC28-121138C7D1A3 @default.
- Q63334832 P4844 Q63334832-41B944C0-7414-4C85-8144-492DBB1E3745 @default.
- Q63334832 P4844 Q63334832-DB18A861-9D23-49FB-AB86-E67B33C32EE3 @default.
- Q63334832 P580 Q63334832-6E366229-5781-4AEB-8349-8465F3ED1101 @default.
- Q63334832 P582 Q63334832-2DC0AE5D-FC80-486F-A36E-CBA249A13D6C @default.
- Q63334832 P6099 Q63334832-791E5B2D-2ACE-4F5F-ACA1-A63AE2414DAE @default.
- Q63334832 P6153 Q63334832-101D43EB-059B-40CE-B3B3-A45D85F3221D @default.
- Q63334832 P6153 Q63334832-4CBDBC85-41CC-4F64-A8D3-E0562FB74E0B @default.
- Q63334832 P6153 Q63334832-A3208FC5-096E-4920-809B-B41EA7D6C61E @default.
- Q63334832 P6153 Q63334832-CAF6A016-5A86-464F-9DA8-D54469B6B002 @default.
- Q63334832 P8363 Q63334832-A83910DC-7D7E-494D-9B16-B14D6A5CCE72 @default.
- Q63334832 P859 Q63334832-2339C990-4A0A-408D-8501-2FADE451A73C @default.
- Q63334832 P1132 "+123" @default.
- Q63334832 P1476 "A Phase Ib, Open-label, Dose-escalation Study of the Safety and Pharmacology of Ipatasertib (GDC-0068) in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors" @default.
- Q63334832 P17 Q142 @default.
- Q63334832 P17 Q145 @default.
- Q63334832 P17 Q29 @default.
- Q63334832 P17 Q30 @default.
- Q63334832 P2899 "+18" @default.
- Q63334832 P3098 "NCT01362374" @default.
- Q63334832 P31 Q30612 @default.
- Q63334832 P4844 Q420436 @default.
- Q63334832 P4844 Q422327 @default.
- Q63334832 P4844 Q423762 @default.
- Q63334832 P580 "2011-07-11T00:00:00Z" @default.
- Q63334832 P582 "2019-06-30T00:00:00Z" @default.
- Q63334832 P6099 Q5452194 @default.
- Q63334832 P6153 Q126412 @default.
- Q63334832 P6153 Q230492 @default.
- Q63334832 P6153 Q30270654 @default.
- Q63334832 P6153 Q30286943 @default.
- Q63334832 P8363 Q78089383 @default.
- Q63334832 P859 Q899140 @default.